Back

Cardiac function and the effect of heart failure treatment in patients with genotype-positive dilated cardiomyopathy

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: focus on remodelling Heart Failure with Mid-Range Ejection Fraction (HFmrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Paul Anders Sletten Olsen

Oslo University Hospital Rikshospitalet, Oslo (Norway)

7 More presentations in this session

Presentation thumbnail
Impact of coronary revascularisation on left ventricular remodelling in ischaemic cardiomyopathy with reduced ejection fraction
Doctor B. Kadyrov (Ashgabat, TM)
Abstract Slides Video
Presentation thumbnail
Monocyte F2RL1 signaling defines an adverse remodeling phenotype in heart failure
Ms E. Ghanbari (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Importance and significance of left atrial reverse remodelling in the follow-up of patients with heart failure
Miss L. Silva (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Early post-surgery left ventricular changes helps to identify patients with residual valvular cardiomyopathy in primary valvular regurgitation
Doctor Y. Kang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of CMR-derived indexed left ventricular end-diastolic volume (LVEDVi) in individuals with preserved and reduced LV ejection fraction - a UK Biobank study
Doctor P. Van Rijckeghem (Aachen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: focus on remodelling

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Contemporary heart failure therapy and left ventricular remodeling in patients with familial dilated cardiomyopathy
17 May 2025
thumbnail
Congress Presentation
The “negative” side of cardiomyopathy: phenotype and arrhythmic risk in gene-elusive patients
28 August 2026
thumbnail
Congress Presentation
Optimal cut-off point of left ventricular ejection fraction for prediction of death in end‑stage hypertrophic cardiomyopathy with systolic dysfunction
28 August 2026
thumbnail
Congress Presentation
Heart failure in dilated/arrhythmogenic cardiomyopathy: insights from the SHaRe cohort
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources